UNSPSC 51172143: Oxyphencyclimine or oxyphencyclimine hydrochloride

This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formulas C20H28N2O3 and C20H28N2O3.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 4V44H1O8XI and GWO1432WOU, the base compound being chemically known as 1,4,5,6-tetrahydro-1-methyl-2-pyrimidinylmethyl alpha-cyclohexyl-alpha-phenylglycolat but generally known as oxyphencyclimine, which bears US NIH Compound Identifier 4642.

UNSPSC 51172143 Oxyphencyclimine or oxyphencyclimine hydrochloride (Commodity) appears in state and local procurement with minimal recent activity directly aligned to this specific pharmaceutical ingredient. The three recent opportunities tagged under this code span offender drug testing services, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals procurement — none of which explicitly names oxyphencyclimine as a line item or procurement target. The Collin County Community Supervision and Corrections Department RFP for offender specimen collection and drug testing (due July 23, 2026, estimated contract value $600,000) solicits testing services and laboratory screening methodologies, not pharmaceutical products themselves. The Texas Health and Human Services Commission RFI regarding direct-to-manufacturer prescriptions (closed April 3, 2026) seeks vendor capabilities for contracting models and program design rather than specific drug inventory. The Minnesota Multistate Cooperative Purchasing Alliance RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026) is a standing cooperative vehicle for manufacturers and wholesalers but does not isolate oxyphencyclimine in its publicly disclosed scope. State and local health departments, corrections agencies, and cooperative purchasing alliances are the issuing bodies, but the code shows no concrete recent solicitations for this particular compound.

The geographic spread of tagged opportunities includes Texas (Collin County and HHS Commission) and Minnesota (MMCAP, serving multiple states including Oregon), yet none of these solicitations demonstrate active demand or differentiated procurement for oxyphencyclimine specifically. The code lacks sufficient recent state and local contract activity to characterize market pursuit or issuing-body concentration. Business development professionals evaluating this code should treat it as a low-activity commodity with misaligned recent opportunity tagging; the source does not support a current procurement signal or clear jurisdictional pattern of buyer interest in this ingredient.